FINWIRES · TerminalLIVE
FINWIRES

Sun Pharma Advanced to Sell Rare Paediatric Disease Priority Review Voucher for $195 Million

By

Sun Pharma Advanced Research Company (NSE:SPARC, BOM:532872) has agreed to sell its rare paediatric disease priority review voucher (PRV) granted by the U.S. Food and Drug Administration ( US FDA) for the approval of Sezaby for $195 million.

PRV was granted by the US FDA for the approval of Sezaby, used to treat neonatal seizures. It is a benzyl alcohol and propylene glycol-free formulation of phenobarbital sodium powder for injection, according to a Thursday filing to the Indian stock exchanges.

The sale of the PRV is expected to help the company develop its pipeline assets and strengthen its external innovation strategy.

The transaction is subject to customary closing conditions, including expiration of the applicable waiting period.

Related Articles

Asia

Joinn Laboratories' Profit Surges 480% in Q1

Joinn Laboratories (HKG:6127, SHA:603127) posted net profit attributable to shareholders of 238.4 million yuan for the first quarter, up 480% from 41.1 million yuan a year earlier, according to a Wednesday Hong Kong bourse filing.Hong Kong-listed shares of the drug research firm were down over 6% in Thursday's late-morning trade.Earnings per share came in at 0.32 yuan, up from 0.05 yuan a year earlier.Revenue increased 10% to 316.1 million yuan from 287.3 million yuan in the prior-year period.

HKG:6127SHA:603127
Asia

Ganfeng Lithium Turns to Q1 Profit as Revenue Jumps 144%

Ganfeng Lithium (SHE:002460, HKG:1772) posted first-quarter attributable net profit of 1.84 billion yuan, compared with loss of 355.8 million yuan the previous year.Earnings per share stood at 0.88 yuan, versus loss per share of 0.18 yuan last year, according to a Thursday filing with the Shenzhen bourse.Operating revenue jumped 144% year over year to 9.20 billion yuan from 3.77 billion yuan.Shares of the lithium miner were up 2% in recent trade on the Shenzhen bourse and 1% on the Hong Kong bourse.

HKG:1772SHE:002460
Asia

Yihai Kerry Arawana Q1 Profit Up 51%, Revenue Rises 11%

Yihai Kerry Arawana (SHE:300999) posted first-quarter attributable net profit of 1.48 billion yuan, up 51% from 981.4 million yuan the previous year.Earnings per share rose to 0.27 yuan from 0.18 yuan, according to a Thursday filing with the Shenzhen bourse.Operating revenue climbed 11% year over year to 65.5 billion yuan from 59.1 billion yuan.Shares of the food products company were up 2% in recent trade.

SHE:300999